Understanding how B cells and fibroblasts interact in lung disease after stem cell transplants
Official title: B Cell-Fibroblast Crosstalk Promotes Chronic GVHD of the Lung
Funded at Duke University · NIH-10950997 · Data updated 2026-11-12
This study is looking at how certain immune cells interact in the lungs to better understand and treat a serious condition called chronic graft-versus-host disease (cGVHD) that can happen after stem cell transplants, with the goal of helping patients feel better and live longer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $104,435 |
| NIH project number | 1K38AI185078-01 |
| Project ID | NIH-10950997 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients who have undergone allogeneic stem cell transplantation and are experiencing chronic graft-versus-host disease affecting their lungs.
✕Less likely to help
Patients who do not have cGVHD or have not undergone stem cell transplantation may not benefit from this research.
What this research studies
This research investigates the interactions between B cells and fibroblasts that contribute to chronic graft-versus-host disease (cGVHD) in the lungs. The principal investigator, Dr. Sonali Bracken, aims to identify immune pathways involved in lung fibrosis, a serious complication that can arise after allogeneic stem cell transplantation. By developing B cell-targeted therapies, the research seeks to improve the health and longevity of patients suffering from autoimmune and fibroproliferative disorders. The study will utilize advanced immunological techniques and data analysis to explore these mechanisms, supported by a multidisciplinary mentorship team.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve lung health and quality of life for patients with cGVHD.
How similar studies have gone: Previous research has shown promise in targeting B cells for the treatment of autoimmune diseases, indicating that this approach may yield beneficial results.
Where this research is happening
-
Duke University
Durham, United States Active
Researchers
- Principal investigator: Bracken, Sonali Jagdish — Duke University
- Study coordinator: Bracken, Sonali Jagdish
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.